Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
53 hedge funds and large institutions have $27.5M invested in Tourmaline Bio in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 13 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.11% less ownership
Funds ownership: 6.55% → 6.43% (-0.11%)
5% less funds holding
Funds holding: 56 → 53 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
61% less capital invested
Capital invested by funds: $71M → $27.5M (-$43.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1.38M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$246K |
| 3 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$128K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$114K |
| 5 |
Two Sigma Investments
New York
|
+$112K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.43M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$521K |
| 3 |
ACM
Aisling Capital Management
New York
|
-$460K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$333K |
| 5 |
Millennium Management
New York
|
-$140K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Fidelity Investments
Boston,
Massachusetts
| $1.19K | +$996 | +62 | +113% |
|
52
Citigroup
New York
| $231 | -$1.09K | -68 | -75% |
|
|
CS
53
Credit Suisse
Zurich,
Switzerland
| $1 | -$209 | -13 | Closed |
|
54
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1.19K | -33,406 | Closed |
|
|
LGM
55
Logos Global Management
San Francisco,
California
| – | -$521K | -19,791 | Closed |
|
|
ACM
56
Aisling Capital Management
New York
| – | -$460K | -17,500 | Closed |
|
|
57
Millennium Management
New York
| – | -$140K | -5,323 | Closed |
|
58
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$78K | -2,967 | Closed |
|
59
BNP Paribas Financial Markets
Paris,
France
| – | -$64.4K | -2,448 | Closed |
|
60
Dimensional Fund Advisors
Austin,
Texas
| – | -$47K | -1,788 | Closed |
|
61
SG Americas Securities
New York
| – | -$27K | -1,040 | Closed |
|
62
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$5K | -178 | Closed |
|
|
CUAMC
63
China Universal Asset Management Company
Shanghai,
China
| – | -$1K | -39 | Closed |
|
TRML Hedge Fund Activity: Q4 2022 in Review
53 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q4 2022, worth a combined $27.5M — down 61% from $71M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TRML and 10 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 17 added.
The largest buyer was Citadel Advisors, adding an estimated $1.38M. The largest seller was BlackRock, cutting an estimated $1.43M.
- 53 institutional investors held Tourmaline Bio (TRML) as of Q4 2022, down from 56 in Q3 2022.
- Funds reported $27.5M of Tourmaline Bio stock for Q4 2022, down 61% quarter-over-quarter.
- 10 funds opened new Tourmaline Bio positions in Q4 2022 and 13 closed out, a net change of -3 holders.
- The largest Tourmaline Bio buyer in Q4 2022 was Citadel Advisors, an estimated $1.38M added.
- The largest Tourmaline Bio seller in Q4 2022 was BlackRock, an estimated $1.43M sold.
Based on aggregated 13F filings for Q4 2022.